ENTA · XBRL financial data

Enanta Pharmaceuticals financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ENTA's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Revenue from contracts with customers	122,473	97,074	86,160	79,204	67,635	65,324
Research and development	136,756	174,111	164,522	163,524	131,476	106,740
General and administrative	27,356	32,536	45,482	52,887	57,850	43,933
Operating income (loss)	(41,639)	(109,573)	(123,844)	(137,207)	(121,691)	(85,349)
Interest expense	—	0	0	5,148	10,940	7,681
Income tax expense (benefit)	1,149	(28,583)	(433)	2,821	(1,743)	(1,660)
Net income (loss)	(36,168)	(78,996)	(121,755)	(133,816)	(116,045)	(81,889)
Earnings per share, basic USD per share	(1.81)	(3.92)	(5.91)	(6.38)	(5.48)	(3.84)
Earnings per share, diluted USD per share	(1.81)	(3.92)	(5.91)	(6.38)	(5.48)	(3.84)
Weighted average shares, basic thousands of shares	19,940	20,171	21	21	21	21
Weighted average shares, diluted thousands of shares	19,940	20,171	21	21	21	21

Fiscal years (ENTA's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Cash and cash equivalents	87,131	57,206	43,994	85,388	37,233	32,298
Marketable securities	299,518	186,796	205,238	284,522	210,953	156,566
Marketable securities, non-current	32,634	108,416	29,285	0	—	0
Accounts receivable	23,492	23,576	20,318	8,614	6,646	6,882
Prepaid and other current assets	26,696	14,188	13,445	13,263	12,413	8,590
Total current assets	436,837	319,021	311,713	422,791	299,852	204,336
Property and equipment, net	8,596	5,943	6,173	11,919	32,688	35,395
Right-of-use asset	7,020	4,711	23,575	22,794	40,658	37,549
Total assets	486,132	438,791	375,410	462,275	376,652	280,732
Accounts payable	5,737	9,540	6,000	4,097	8,002	1,948
Accrued liabilities	14,159	22,429	20,936	18,339	13,547	12,751
Total current liabilities	24,157	36,172	29,827	62,787	57,535	48,555
Lease liability, non-current	3,838	1,126	22,372	21,238	53,943	54,757
Total liabilities	30,552	39,362	54,076	245,540	247,838	216,015
Retained earnings (accumulated deficit)	127,572	48,576	(73,179)	(206,995)	(323,040)	(404,929)
Total stockholders' equity	455,580	399,429	321,334	216,735	128,814	64,717
Total liabilities and equity	486,132	438,791	375,410	462,275	376,652	280,732
Common shares outstanding (cover page) thousands of shares	20,079	20,325	20,797	21,059	21,194	28,863

Fiscal years (ENTA's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Net income (loss)	(36,168)	(78,996)	(121,755)	(133,816)	(116,045)	(81,889)
Stock-based compensation	19,575	20,991	26,969	28,216	26,795	18,565
Net cash from operating activities	7,088	(69,996)	(84,782)	(103,154)	(78,764)	(19,272)
Purchases of property and equipment	1,445	750	2,125	9,058	17,948	12,896
Net cash from investing activities	19,830	36,991	54,897	(53,578)	58,235	40,347
Proceeds from issuing equity	10,481	3,614	—	—	—	—
Net cash from financing activities	8,983	3,080	20,033	198,126	(27,626)	(26,618)
Net change in cash	35,901	(29,925)	(9,852)	41,394	(48,155)	(5,543)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Enanta Pharmaceuticals	33,419	14,359	(9,972)*	29.1M	19.0 quarters	Q3 FY26 10-QJun 30, 2026
TuHURA Biosciences	996	not reported	(8,634)*	63.7M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Galectin Therapeutics	13,269	not reported	(2,439)*	100.8M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Protara Therapeutics	17,076	not reported	(15,389)*	59.1M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Cartesian Therapeutics	147,606	0	(21,082)*	30.3M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Caribou Biosciences	26,194	1,499	(22,787)*	107.2M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Fate Therapeutics	32,429	2,082	(23,400)	119.8M	6.6 quarters	Q2 FY26 10-QJun 30, 2026
Protalix BioTherapeutics	27,420	19,896	(10,400)*	80.6M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Atossa Therapeutics	26,094	not reported	(9,644)*	10.0M	2.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.